Literature DB >> 16127165

Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.

Martin Köbel1, Gudrun Pohl, Wolfgang D Schmitt, Steffen Hauptmann, Tian-Li Wang, Ie-Ming Shih.   

Abstract

Placental site trophoblastic tumor (PSTT) is a gestational neoplasm derived from the extravillous (intermediate) trophoblast of the implantation site. PSTT is characterized by a highly invasive phenotype, but the molecular mechanisms are poorly understood. In this report, we demonstrate that PSTTs expressed the activated (phosphorylated) form of mitogen-activated protein kinase (MAPK) in 84% of cases, whereas the normal extravillous trophoblastic cells did not. To characterize the role of MAPK activation in PSTT, we established the first PSTT cell culture, IST-2, from a surgically resected PSTT. IST-2 cells expressed HLA-G and Mel-CAM but not E-cadherin, an immunophenotype characteristic of PSTT. IST-2 cells were highly motile and invasive in culture as compared to choriocarcinoma JEG-3 cells and normal extravillous trophoblastic cells. Based on wound assay, time-lapse videomicroscopy for cell tracking, and invasion chamber assays, we found that the motility and invasion of IST-2 cells were significantly reduced (P<0.01) after treatment with the MEK inhibitors CI-1040 and PD 59089, which prevent activation of MAPK. In contrast, neither compound had any effect on normal extravillous trophoblastic cells or JEG-3 cells. In conclusion, our findings demonstrate a functional role of MAPK activation in the motility and invasion of PSTT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127165      PMCID: PMC1698728          DOI: 10.1016/s0002-9440(10)62059-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Constitutive activation of MAP kinase kinase (MEK1) is critical and sufficient for the activation of MMP-2.

Authors:  H Kurata; A A Thant; S Matsuo; T Senga; K Okazaki; N Hotta; M Hamaguchi
Journal:  Exp Cell Res       Date:  2000-01-10       Impact factor: 3.905

2.  Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood.

Authors:  Y Tanigawara; T Kita; M Hirono; T Sakaeda; F Komada; K Okumura
Journal:  Ther Drug Monit       Date:  2001-08       Impact factor: 3.681

3.  Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells.

Authors:  C F Lai; L Chaudhary; A Fausto; L R Halstead; D S Ory; L V Avioli; S L Cheng
Journal:  J Biol Chem       Date:  2001-01-29       Impact factor: 5.157

Review 4.  Development of anticancer drugs targeting the MAP kinase pathway.

Authors:  J S Sebolt-Leopold
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

Review 5.  Molecular basis of gestational trophoblastic diseases.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Curr Mol Med       Date:  2002-02       Impact factor: 2.222

6.  Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.

Authors:  Gudrun Pohl; Chung-Liang Ho; Robert J Kurman; Robert Bristow; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

7.  HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis.

Authors:  Gad Singer; Robert J Kurman; Michael T McMaster; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2002-07       Impact factor: 6.394

8.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

Authors:  Harith Rajagopalan; Alberto Bardelli; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion.

Authors:  D J Webb; D H Nguyen; S L Gonias
Journal:  J Cell Sci       Date:  2000-01       Impact factor: 5.285

View more
  6 in total

1.  Up-regulation of CD81 inhibits cytotrophoblast invasion and mediates maternal endothelial cell dysfunction in preeclampsia.

Authors:  Li Shen; Zhenyu Diao; Hai-Xiang Sun; Gui-Jun Yan; Zhiqun Wang; Ruo-Tian Li; Yimin Dai; Jingmei Wang; Jie Li; Hailing Ding; Guangfeng Zhao; Mingming Zheng; Pingping Xue; Mo Liu; Yan Zhou; Yali Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

2.  The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1.

Authors:  Jim Jinn-Chyuan Sheu; Jung Hye Choi; Isil Yildiz; Fuu-Jen Tsai; Yosef Shaul; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

3.  Down-regulation of endothelial protein C receptor promotes preeclampsia by affecting actin polymerization.

Authors:  Hao Wang; Pan Wang; Xiaoling Liang; Wenjing Li; Mo Yang; Jihong Ma; Wei Yue; Shangrong Fan
Journal:  J Cell Mol Med       Date:  2020-01-30       Impact factor: 5.310

Review 4.  A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors.

Authors:  Xuan Feng; Zhi Wei; Sai Zhang; Yan Du; Hongbo Zhao
Journal:  Front Oncol       Date:  2019-11-28       Impact factor: 6.244

5.  Expression profiling of lncRNAs and mRNAs in placental site trophoblastic tumor (PSTT) by microarray.

Authors:  Jianfeng Gan; Zhixian Chen; Xuan Feng; Zhi Wei; Sai Zhang; Yan Du; Congjian Xu; Hongbo Zhao
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

6.  Inhibitory Effects of PC-SPESII Herbal Extract on Human Breast Cancer Metastasis.

Authors:  Xiu-Feng Wang; Jia Du; Tian-Ling Zhang; Qian-Mei Zhou; Yi-Yu Lu; Hui Zhang; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-25       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.